newsfilter
← Latest News
Business Wire·

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS) in Q2 2025 Continued progress in the Phase 2 TibuSURE clinical study